Brain monoamine oxidase (MAO) converts dopamine into inactive substance. By blocking MAO, more dopamine is available. MAO–B inhibitors don’t have the same side effects as MAO-A inhibitors, and therefore side effects associated with elevated concentrations of adrenaline-like substances –as, for example, hypertension-are avoided.
Since MAO-B inhibitors do provide modest benefit for the motor features of PD, they are usually used as early monotherapy or as an adjunct (add-on) to other medications, including levodopa. When used in combination with other medications, MAO-B inhibitors may reduce “off” time and extend “on” time.
|
Presentation |
Dosages in Milligrams |
Typical Treatment Regimens |
Indications for Usage |
|
Selegiline (l-deprenyl, Eldepryl®) |
5 |
5 mg twice a day |
Monotherapy for slowness, stiffness, and tremor; adjunct therapy for motor fluctuations |
|
Rasagiline (Azilect®) |
0.5, 1.0 |
1 mg once daily |
Same as above |
|
Zydis selegiline HCL Oral disintegrating (ZELAPAR®) |
1.25, 2.5 |
1.25-2.5 mg once daily |
Same as above |
Note: Taking MAO-B inhibitors with the heavy consumption of aged cheeses or wines high in tyramine may raise blood pressure to dangerous levels.
Ahlskog JE. Parkinson’s Disease Treatment Guide for Physicians. New York, NY: Oxford University Press; 2009.
Ahlskog JE. The Parkinson’s Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications. New York, NY: Oxford University Press; 2005.